{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T09:38:40Z","timestamp":1778319520055,"version":"3.51.4"},"reference-count":39,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2011,10,25]],"date-time":"2011-10-25T00:00:00Z","timestamp":1319500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To systematically review the literature on generic antiepileptic drugs (AEDs), evaluate the efficacy and safety of generic AED substitution, and perform pharmacokinetic (PK) analysis using the American Academy of Neurology (AAN) scheme to classify evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>PubMed and Cumulative Index to Nursing and Allied Health Literature searches from January 1, 1980, to October 15, 2010, were performed using the search terms anticonvulsant, antiepileptic drug, carbamazepine, divalproex, ethosuximide, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, ph\u00e9nobarbital, Phenytoin, primidone, topiramate, valproate, valproic acid, and zonisamide; bioavailability, bioequivalence, bioequivalency, bioequivalent, and substitution; and generic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Retrospective and prospective controlled studies of generic substitution of AEDs were included in the review. Non-English-language articles and uncontrolled clinical studies were excluded, Published articles were categorized using the AAN criteria for systematic reviews.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>We identified 156 articles. Of these, 20 met our inclusion criteria; 7 were retrospective studies, 6 were prospective studies in patients with epilepsy, and 7 were prospective studies in healthy subjects. All articles were rated Class I to Class III, using AAN criteria. The retrospective studies were categorized as Class III and showed a significant relationship between generic substitution and increased use of health care resources because of seizures or AED toxicity. Prospective studies were categorized as Class I, II, and III. Prospective studies in patients showed no differences between brand and generic drugs in PK parameters of bioequivalence. Three prospective studies in healthy subjects reported significant differences in maximum drug concentrations. Comparison of brand and generic drugs revealed no significant difference in seizure frequency; however, some prospective studies showed significant differences in PK parameters, primarily those not used for bioequivalence determinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>There is inconsistency between retrospective and prospective studies of generic AED substitution. The highest levels of evidence indicate that there should not be a problem with generic substitution, although some patients are more prone to problems with the generic products. Some evidence suggests that switches between multiple generic AED products in certain individuals may be problematic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1q349","type":"journal-article","created":{"date-parts":[[2011,10,25]],"date-time":"2011-10-25T23:22:31Z","timestamp":1319584951000},"page":"1406-1415","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":40,"title":["Generic Substitution of Antiepileptic Drugs: A Systematic Review of Prospective and Retrospective Studies"],"prefix":"10.1177","volume":"45","author":[{"given":"Mikiko","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, University of Kansas, Kansas City, KS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy E","family":"Welty","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, University of Kansas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2011,10,25]]},"reference":[{"key":"bibr1-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01927.x"},{"key":"bibr2-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2007.03.014"},{"key":"bibr3-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318167d11b"},{"key":"bibr4-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002216.pub2"},{"key":"bibr5-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-9-11"},{"key":"bibr6-aph.1Q349","unstructured":"Epilepsy Foundation Board of Directors. Position on switching of antiepileptic drugs, www.epilepsyfoundation.org\/advocacy\/care\/genedrev.cfm (accessed 2010 May 31)."},{"key":"bibr7-aph.1Q349","unstructured":"American Epilepsy Society. The substitution of different formulations of antiepileptic drugs for the treatment of epilepsy, www.aesnet.org\/index.cfm?objectid=77B16A48-E7FF-0F41-218E9CB3E54919D4 (accessed 2010 Jun 30)."},{"key":"bibr8-aph.1Q349","unstructured":"Epilepsy Society of Australia Committee. ESA position statement: generic drug use in epilepsy. www.epilepsy-society.org.au\/pages\/guidelines2.php (accessed 2011 Aug 23)."},{"key":"bibr9-aph.1Q349","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research. Statistical criteria for bioequivalence. In: Food and Drug Administration, Center for Drug Evaluation and Research, Office of Generic Drugs, eds. Approved drug products with therapeutic equivalence evaluations. 31 st ed. Washington, DC: US Department of Health and Human Services, 2011, viii-ix."},{"key":"bibr10-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M141"},{"key":"bibr11-aph.1Q349","unstructured":"Bureau of Policy, Science and International Programs, Therapeutic Products Directorate. Guidance for industry: bioequivalence requirements: critical dose drugs. www.fda.gov\/Drugs\/InformationOnDrugs\/ucm129662.htm (accessed 2011 Jul 28)."},{"key":"bibr12-aph.1Q349","unstructured":"Committee for Medical Products for Human Use (CHMP). Narrow therapeutic index drugs. In: European Medicines Agency, ed. London: European Medicines Agency, 2010:16."},{"key":"bibr13-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.2165\/10898530-000000000-00000"},{"key":"bibr14-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02299.x"},{"key":"bibr15-aph.1Q349","author":"Edlund W","year":"2005","journal-title":"Clinical practice guideline process manual. 2004 ed. St. Paul, MN: American Academy of Neurology"},{"key":"bibr16-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01007.x"},{"key":"bibr17-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.90"},{"key":"bibr18-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181df091b"},{"key":"bibr19-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.7.769"},{"key":"bibr20-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181aa5300"},{"key":"bibr21-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01703.x"},{"key":"bibr22-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000313154.55518.25"},{"key":"bibr23-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050443"},{"key":"bibr24-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1177\/106002809703100504"},{"key":"bibr25-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.6.1147"},{"key":"bibr26-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.1990.tb10813.x"},{"key":"bibr27-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1989.tb05283.x"},{"key":"bibr28-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1982.tb05062.x"},{"key":"bibr29-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.02.001"},{"key":"bibr30-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.10.018"},{"key":"bibr31-aph.1Q349","first-page":"699","volume":"47","author":"Revankar SN","year":"1999","journal-title":"J Assoc Physicians India"},{"key":"bibr32-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70132-3"},{"key":"bibr33-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-081X(199901)20:1<19::AID-BDD152>3.0.CO;2-Q"},{"key":"bibr34-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011929300613"},{"key":"bibr35-aph.1Q349","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01414.x"},{"key":"bibr36-aph.1Q349","unstructured":"Center for Drug Evaluation and Research, Food and Drug Administration. Therapeutic equivalence evaluations codes. http:\/\/webcache.googleusercontent.com\/search?q=cache:H_10U62vAwYJ:www.fda.gov\/drugs\/developmentapprovalprocess\/ucm079068.htm+AA+rate+AB+rate+generic&cd=8&hl=en&ct=clnk&gl=us&source=www.google.com (accessed 2011 Aug 3)."},{"key":"bibr37-aph.1Q349","unstructured":"Centers for Disease Control and Prevention. Data & statistics. www.cdc.gov\/epilepsy\/ (accessed 2011 Aug 3)."},{"key":"bibr38-aph.1Q349","unstructured":"KobauR, ZahranH, ThurmanDJ. Epilepsy surveillance among adults\u201419 states, behavioral risk factor surveillance system, 2005. www.cdc.gov\/mmwr\/preview\/mmwrhtml\/ss5706a1.htm?s_cid=ss5706a1_e (accessed 2011 Aug 3)."},{"key":"bibr39-aph.1Q349","unstructured":"Food and Drug Administration. Summary minutes of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology\/UCM272111.pdf (accessed 2011 Oct 6)."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1Q349","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1Q349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:08:11Z","timestamp":1777374491000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1Q349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,25]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1345\/aph.1Q349"],"URL":"https:\/\/doi.org\/10.1345\/aph.1q349","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,25]]}}}